7.5 C
London
Friday, March 29, 2024
HomeFinTechImugene: Receives key U.S. patent for cancer therapies

Imugene: Receives key U.S. patent for cancer therapies

Date:

  • Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
  • The patent protects Imugene’s B-Cell immunotherapy portfolio, which includes a range of cancer vaccines
  • Specifically, the new patient protects the composition and use of the vaccines, which are licenced by Ohio State University
  • Imugene’s CEO and Managing Director, Leslie Chong, said winning the key U.S. patent is a significant step for the company
  • The patent is valid up until 2035
  • Today, Imugene shares are up 3.92 per cent to trade for 5.3 cents each

Related stories

Tide names former SVP George Schmidt as new regional CEO for UK and Europe

George Schmidt, formerly the senior VP of marketing...

UK paytech Volopa partners ClearBank to expand its SME banking services

London-based paytech Volopa has partnered with embedded banking...

Digital identity specialist Signicat acquires Icelandic counterpart SmartWorks

Signicat, a European provider of digital identity solutions,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

spot_img